博济医药(300404) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was CNY 74,184,304.67, representing a 34.28% increase compared to CNY 55,245,275.36 in the same period last year[4] - Net profit attributable to shareholders was CNY 12,461,872.32, a significant increase of 69.11% from CNY 7,369,156.02 year-on-year[4] - The company achieved total revenue of approximately CNY 74.18 million, representing a year-on-year growth of 34.28%[16] - Net profit attributable to shareholders reached approximately CNY 12.46 million, with a year-on-year increase of 69.11%[16] - Net profit for the period was ¥12,958,997.65, representing a 30.7% increase from ¥9,899,292.90 in the same quarter last year[26] - The total comprehensive income attributable to the parent company was CNY 12,328,659.62, an increase from CNY 7,462,056.88 in the previous period, representing a growth of approximately 65.5%[27] Cash Flow - The net cash flow from operating activities reached CNY 13,226,796.84, up 76.57% from CNY 7,490,830.80 in the previous year[4] - Cash inflow from operating activities totaled CNY 101,364,592.07, compared to CNY 70,467,706.01 in the prior period, reflecting a rise of approximately 43.8%[28] - The cash outflow from investment activities was CNY 306,663,248.49, significantly higher than CNY 69,796,489.65, resulting in a net cash flow from investment activities of -CNY 215,913,864.22[29] - The company reported a net cash flow from financing activities of -CNY 12,561,361.04, worsening from -CNY 5,097,434.12 in the prior period[29] - The cash and cash equivalents at the end of the period were CNY 169,088,595.83, compared to CNY 137,507,691.92 at the end of the previous period, showing an increase of about 23.0%[29] Research and Development - Research and development expenses increased by 30.71% to CNY 8,513,725.40, reflecting the company's commitment to enhancing R&D efforts[8] - Research and development expenses increased to ¥8,513,725.40, up 30.6% from ¥6,513,359.61 in the previous year[26] Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,147,315,639.13, a 0.80% increase from CNY 1,138,209,210.53 at the end of the previous year[4] - The total liabilities decreased to ¥287,991,515.59 from ¥291,831,403.77, a reduction of 1.3%[24] - The total owner's equity rose to ¥859,324,123.54 from ¥846,377,806.76, an increase of 1.7%[24] Investment and Financing - The company reported a significant increase in investment income, which rose by 176.80% to CNY 403,361.65 compared to a loss of CNY 525,223.30 in the previous year[8] - The financing credit limit for the company and its subsidiaries was increased from CNY 300 million to CNY 500 million[18] - The company plans to use up to CNY 100 million of idle raised funds to temporarily supplement working capital[17] Shareholder Information - The company’s major shareholder, Wang Tingchun, holds 29.21% of the shares, with 57.28 million shares pledged[14] - The company approved a stock option incentive plan, granting 2.699 million stock options to 86 eligible participants[19] Contracts and Services - New contract amounts increased by approximately CNY 200 million, a year-on-year growth of about 104%[16] - The company reported a new contract amount of approximately CNY 150 million for clinical research services, up 118% year-on-year[16] - The company’s clinical research services and preclinical research services saw contract amounts grow by 118% and 148% respectively[16] Other Information - The weighted average return on equity slightly decreased to 1.52% from 1.64% in the previous year[4] - The company did not conduct any mergers or acquisitions during the reporting period, as indicated by the net profit from merged entities being CNY 0.00[27] - The report was not audited, as stated in the audit report section[30]